Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ambry Genetics | RCV002340961 | SCV002643811 | uncertain significance | Cardiovascular phenotype | 2024-10-19 | criteria provided, single submitter | clinical testing | The p.G1751D variant (also known as c.5252G>A), located in coding exon 13 of the TNXB gene, results from a G to A substitution at nucleotide position 5252. The glycine at codon 1751 is replaced by aspartic acid, an amino acid with similar properties. This amino acid position is conserved. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |
Mayo Clinic Laboratories, |
RCV004793777 | SCV005412105 | uncertain significance | not provided | 2024-09-09 | criteria provided, single submitter | clinical testing | BP4 |
Fulgent Genetics, |
RCV005032245 | SCV005669515 | uncertain significance | Ehlers-Danlos syndrome due to tenascin-X deficiency; Vesicoureteral reflux 8 | 2024-02-06 | criteria provided, single submitter | clinical testing |